INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($1.05), $0.65 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance